(Q51084928)

29 March 2018

title

The schizophrenia ketamine challenge study debate. (English)

1 reference

29 March 2018

0 references

Carpenter WT Jr

1

1 reference

29 March 2018

language of work or name

English

0 references

publication date

1 October 1999

1 reference

29 March 2018

number of pages

11

1 reference

based on heuristic

inferred from page(s)

published in

Biological Psychiatry

1 reference

29 March 2018

volume

46

1 reference

29 March 2018

page(s)

1081-1091

1 reference

29 March 2018

issue

8

1 reference

29 March 2018

The MacArthur Treatment Competence Study. I: Mental illness and competence to consent to treatment

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

The risk of medication-free research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

The rationale and ethics of medication-free research in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium; II. Symbolic and sequential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

The effect of 1-arylcylohexylamine (sernyl) on twelve normal volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Neuroleptic withdrawal in schizophrenic patients. A review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Ketamine sedation for pediatric procedures: Part 2, Review and implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Recent advances in the phencyclidine model of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Does a four-week delay in the introduction of medication alter the course of functional psychosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Ketamine activates psychosis and alters limbic blood flow in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Absence of ketamine effects on memory and other cognitive functions in schizophrenia patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Ethical problems in psychiatric research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Provocative tests with psychostimulant drugs in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Methylphenidate challenge as a predictor of relapse in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Prediction of relapse in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Model psychoses and schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

The apolipoprotein E epsilon 4 allele is associated with blunting of ketamine-induced psychosis in schizophrenia. A preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Psychiatric symptom-provoking studies: an ethical appraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Glutamate receptor dysfunction and schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Comparison of sernyl with other drugs: simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Are there long-term effects of ketamine on the central nervous system?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Ethical parameters of challenge studies inducing psychosis with ketamine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Interaction of phencyclidine ("angel dust") with a specific receptor in rat brain membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Neuroleptics and the Natural Course of Schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Risks of withdrawing antipsychotic medications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

Specific [3H]phencyclidine binding in rat central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900194-8

10.1016/S0006-3223(99)00194-8

7 January 2021

Identifiers

DOI

1 reference

29 March 2018

PubMed ID

10536744

1 reference

29 March 2018